These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 25817265)
1. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20. Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265 [No Abstract] [Full Text] [Related]
2. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H; Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927 [TBL] [Abstract][Full Text] [Related]
4. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Wright NA; Piggott CD; Eichenfield LF Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304 [No Abstract] [Full Text] [Related]
5. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study. Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799 [No Abstract] [Full Text] [Related]
6. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Downs AM Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344 [No Abstract] [Full Text] [Related]
7. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Levine D; Strober BE Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Reich K; Burden AD; Eaton JN; Hawkins NS Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity? van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798 [No Abstract] [Full Text] [Related]
11. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Al-Mutairi N; Nour T Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040 [TBL] [Abstract][Full Text] [Related]
12. Switching biologics in severe pediatric psoriasis: a retrospective analysis. Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270 [No Abstract] [Full Text] [Related]
13. Experience with biologics for psoriasis in daily practice: switching is worth a try. Lecluse LL; de Groot M; Bos JD; Spuls PI Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876 [No Abstract] [Full Text] [Related]
14. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab. Brunasso AM; Puntoni M; Delfino C; Massone C Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100 [No Abstract] [Full Text] [Related]
15. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. Ortonne JP; Shear N; Shumack S; Henninger E; BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548 [TBL] [Abstract][Full Text] [Related]
16. Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy. Sano S J Dermatol; 2017 Oct; 44(10):e234-e235. PubMed ID: 28623843 [No Abstract] [Full Text] [Related]
17. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. Medina-Gil C; Dehesa L; Vega A; Kerdel F Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of Phototherapy in the Age of Biologics. Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]